{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.4","upperLimit":"55.4","value":"43.7"}]}],"title":"Two-year overall survival"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.3","upperLimit":"44.5","value":"32.9"}]}],"title":"Five-year overall survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"We reported overall survival at 2 years and 5 years after transplant","dispersionType":"95% Confidence Interval","groups":[{"description":"Although the protocol initially had different disease intensities, ultimately, moved to one regimen for all patients. Subjects received 30mg/m\\^2 of Fludarabine from Day-7 until Day-3, 140mg/m\\^2 of Melphalan on Day-2, and 1.5mg/kg of Rabbit antithymocyte globulin at Day-7,-5,-3 and -1.\"","id":"OG000","title":"Treatment Group"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Overall Survival- Percentage of Participants Who Survived at 2 Years and 5 Years","type":"SECONDARY","unitOfMeasure":"percentage of patients"}